Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Eckert & Ziegler SE's average EBITDA Per Share Growth Rate was 11.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.40% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.00% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 14.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Eckert & Ziegler SE was 65.80% per year. The lowest was -13.40% per year. And the median was 9.30% per year.
Eckert & Ziegler SE (CHIX:EUZd) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Eckert & Ziegler SE 5-Year EBITDA Growth Rate Related Terms
CHIX:EUZD vs ABT, SYK, MDT: 5-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Eckert & Ziegler SE's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE 5-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's 5-Year EBITDA Growth Rate falls into.
Eckert & Ziegler SE 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 5-Year EBITDA Growth Rate of 15.00% mean?
Eckert & Ziegler SE (CHIX:EUZD) has a 5-Year EBITDA Growth Rate of 15.00% as of Jun. 2026. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Eckert & Ziegler SE and its competitors.
Is Eckert & Ziegler SE's 5-Year EBITDA Growth Rate too high?
Eckert & Ziegler SE's current 5-Year EBITDA Growth Rate is 15.00%. Overall, Eckert & Ziegler SE has a GF Score™ of 98/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's 5-Year EBITDA Growth Rate compare to ABT and SYK?
Eckert & Ziegler SE's 5-Year EBITDA Growth Rate of 15.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
A good 5-Year EBITDA Growth Rate depends on the Medical Devices & Instruments industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Eckert & Ziegler SE and its competitors. Eckert & Ziegler SE's current 5-Year EBITDA Growth Rate is 15.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Based on GuruFocus' analysis, Eckert & Ziegler SE (CHIX:EUZD) is currently considered Modestly Undervalued. The stock's GF Value™ is €15.91, compared to a current price of €13.36 — trading 16% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 15.00%. Eckert & Ziegler SE's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Eckert & Ziegler SE (CHIX:EUZD), the current 5-Year EBITDA Growth Rate is 15.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (CHIX:EUZD) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €13.36 is trading 16% below its estimated GF Value™ of €15.91.
GuruFocus considers Eckert & Ziegler SE to be Modestly Undervalued.
Key valuation signals for CHIX:EUZD:
5-Year EBITDA Growth Rate: 15.00%
GF Value™: €15.91 vs. price of €13.36 (16% below fair value)
No single metric tells the full story. See the CHIX:EUZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
98GF Score
Get the complete analysis for CHIX:EUZD
5-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:EUZD has been successfully added to your 
